Navigation Links
Do Blacks Have Genetic Weakness to Asthma?
Date:9/30/2007

gement when income fell well below the poverty line.

The San Francisco researchers said they adjusted for socioeconomic factors, "but even when one looks at such factors, there are differences that often go unincorporated because they are not easy to handle," Smith said. "Housing quality, segregation in the neighborhood, these are things that generally are not accounted for when you control for socioeconomic status. And the experience of race is complicated, and the measures you have to look at socioeconomic status generally are broad."

Those factors mean that "a genetic explanation needs to pass a high bar to come to that conclusion," Smith said.

The worse outcome for blacks could be partially explained by another factor noted in the study, Smith said, that blacks were less likely to achieve control of their asthma with medications. "There are substantial differences in medication use, and that is an important thing to recognize as a possible contributor," she said.

Dr. Ronina Covar, a staff physician at the National Jewish Medical and Research Center in Denver, said the strength of the new study is that it eliminates one confounding factor from previous studies. "In this case, they all had equal health care," she said.

But "they obviously don't present any genetic data," Covar said. Still, she said, genetics "could be one of the mechanisms and possible explanations for the findings."

More information

To learn more about asthma, visit the U.S. National Library of Medicine.



SOURCES: Lauren Smith, M.D., associate professor, pediatrics, Boston University; Ronina Covar, M.D., staff physician, National Jewish Medical and Research Center, Denver; Sept. 24, 2007, Archives of Internal Medicine


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Page: 1 2

Related medicine news :

1. Blacks decline Lung cancer surgery
2. Fewer Blacks Undergo Lung Cancer Surgery
3. Home Remedies More Used By Blacks And Native Americans
4. Malfunction Of Key Growth Factor Increases Mortality Rate From Pulmonary Fibrosis In Blacks
5. Blacks and East Asians Prone To Side Effects of Cardiovascular Drugs
6. U.S: Prize for the best hearing category (ethnic groups) goes to…. Non-Hispanic Blacks
7. Genes May Trigger Repeated Premature Birth In Blacks
8. Bladder Cancer Has Worse Outcomes In Blacks
9. US Experts Necessitated On An Action Plan To Curb AIDS In Blacks
10. Blacks Get Treatment on Par With Whites for Cardiovascular Disease
11. Hospitals in Older Cities Close Down, Blacks Worst Affected
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting 2New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 1Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 2Hospital Financials Have Recovered to Pre Recession Levels According to Thomson Reuters Study 60953 3Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 1Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin 60950 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 1Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 6076 3
Other Medicine Technology:CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7